

SEQUENCE LISTING

<110> YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW

<120> Anti-NLS substances and uses thereof in nuclear import inhibition

<130> Loyter-NLS

<140> 14286/WO/02

<141> 2003-04-21

<150> IL149279

<151> 2002-04-22

<160> 16

<170> PatentIn Ver. 2.1

<210> 1

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:random insert
of CDR3 region from peptide library - Abl DNA

<400> 1

attagtagtg at

12

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CDR3 random
insert of Abl

<400> 2

Ile Ser Ser Asp

1

<210> 3

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CDR3 random
insert of Ab2 DNA

<400> 3

gcttttatga agagtggtaa gcgttttatt cat

33

<210> 4

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CDR3 random
insert sequence of Ab2

<400> 4

Ala Phe Met Lys Ser Gly Lys Arg Phe Ile His

1

5

10

<210> 5

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CDR3 random
insert sequence of Ab3 DNA

<400> 5

cattttcatt ataagggtaa gcttcagacg ttt

33

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:CDR3 random
insert of Ab3

<400> 6

His Phe His Tyr Lys Gly Lys Leu Gln Thr Phe
1 5 10

<210> 7

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SV40-NLS with
extra C

<400> 7

Pro Lys Lys Lys Arg Lys Val Cys
1 5

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SV40-NLS
-reverse with extra C

<400> 8

Cys Val Lys Arg Lys Lys Lys Pro Gly
1 5

<210> 9

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:VprN with extra
C

<400> 9

Cys Asn Glu Trp Thr Leu Glu Leu Leu Glu Glu Leu Lys Asn Glu Ala
1 5 10 15

Val Arg His Phe
20

<210> 10
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VprC with extra
C

<400> 10
Cys Arg His Ser Arg Ile Gly Val Thr Arg Gln Arg Arg Ala Arg Asn
1 5 10 15

Gly Ala Ser Arg Ser
20

<210> 11
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:VprN mutant
with extra C

<400> 11
Cys Asn Glu Ala Thr Leu Glu Leu Leu Pro Glu Leu Lys Asn Pro Ala
1 5 10 15

Val Arg His Phe
20

<210> 12
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ARM with extra
C

<400> 12
Cys Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn
1 5 10 15

<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Tat short NLS

<400> 13
Cys Gly Arg Lys Lys Arg
1 5

<210> 14
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer LMB3

<400> 14
caggaaacag ctatgac 17

<210> 15
<211> 17
<212> DNA
<213> Artificial Sequence.

<220>
<223> Description of Artificial Sequence:PCR primer
fdSEQ

<400> 15
gaattttctg tatgagg 17

<210> 16
<211> 20
<212> PRT
<213> bacteriophage fd

<400> 16
Ala Glu Gly Asp Asp Pro Ala Lys Ala Ala Phe Asp Ser Leu Gln Ala
1 5 10 15

WO 03/089472

6/6

PCT/IL03/00328

Ser Ala Thr Glu
20